Acelyrin urges stockholders to vote for proposed merger with Alumis
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SLRN:
Disclaimer & DisclosureReport an Issue
ACELYRIN, INC. Amends Merger Agreement with Alumis
Alumis and Acelyrin sign ammended merger agreement
SLRN Earnings this Week: How Will it Perform?
Acelyrin adopts limited-duration stockholder rights plan
Acelyrin says Concentra indication not expected to result in superior proposal
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
6 days ago
- Business Insider
3 'Strong Buy' Value Stocks to Buy Now, 8/13/2025, According to Analysts
Value stocks offer stability for investors by focusing on companies that seem underpriced compared to their actual worth. This approach involves looking for stocks with strong fundamentals and growth potential. By investing in these stocks, investors can achieve significant returns once the market recognizes their true value. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. One way to identify value stocks is by comparing a company's price-to-earnings (P/E) ratio with industry averages or its historical P/E ratios. This ratio compares a company's stock price to its earnings per share. It must be noted that a lower P/E ratio may indicate that the stock is undervalued. Along with this, we have zeroed in on stocks that have received 'Strong Buy' ratings from Wall Street analysts. Here Are This Week's Stocks NICE Ltd. (NICE) – This software company provides cloud and on-premises solutions for customer experience, compliance, and financial crime prevention. It has a Strong Buy analyst consensus rating and an average price target of $206.14, implying a 39.05% upside potential from the current levels. The company's P/E of 19.82x reflects a 29.5% discount to the Technology sector's median of 28.10. Delta Air Lines (DAL) – This major American airline provides domestic and international passenger and cargo services. Its average price target of $67.50 implies a 14.93% upside potential from the current levels. DAL stock has a Strong Buy consensus rating. Trading at a P/E of 8.48x, the company is valued 66.1% below the Industrial sector's median multiple of 25.00. Post Holdings (POST) – This consumer packaged goods company is known for its branded and private-label foods. It has a Strong Buy analyst consensus rating and an average price target of $127.70, implying a 17.73% upside potential from the current levels. With a P/E ratio of 18.33x, the stock is priced at an 18.1% discount to the Consumer Defensive sector's median of 22.38. What Is TipRanks' Smart Value Newsletter? TipRanks' Smart Value Newsletter helps investors identify high-potential value stocks with strong fundamentals and long-term growth potential, based on TipRanks' data and analysis. The newsletter, published weekly, includes macroeconomic, market-wide, and company-specific analysis to help investors understand the trends that affect value investing.
Medscape
07-08-2025
- Medscape
FDA Approves Drug for Aggressive Glioma
The FDA has granted accelerated approval to dordaviprone (Modeyso, Jazz Pharmaceuticals) for H3 K27M-mutant diffuse glioma, marking the first time a systemic therapy has been approved for the aggressive glioma subtype. H3 K27M-mutant diffuse glioma is a grade 4 midline tumor that primarily affects children and young adults. Median survival is about a year. Historically, treatment has been limited to radiation, with few options available after recurrence besides palliative care. Dordaviprone is a first-in-class oral imipridone that disrupts tumor cell metabolism and increases tumor susceptibility to immune-mediated attack. Jazz Pharmaceuticals bought Chimerix in early 2025 for almost $1 billion based on dordaviprone's commercial prospects. 'Dordaviprone has the potential to rapidly become a standard of care for a rare oncology disease and also contribute durable revenue beginning in the near-term,' Jazz CEO Bruce Cozadd, said in a press release at the time. Approval was based on a pooled analysis of five single-arm studies enrolling 46 adults and four children with recurrent tumors previously treated with radiation, according to a statement from the FDA. Adults received 625 mg once weekly while pediatric patients received lower, weight-adjusted weekly doses. Mutation status was confirmed by immunohistochemistry or sequencing of archival tumor tissue. The overall response rate was 22%. The median time to response was 8.3 months, and the median duration of response (DOR) was 10.3 months. Among 11 patients with objective responses, 73% had a DOR of at least 6 months, and 27% had a DOR of at least 12 months. Seven of 15 evaluable patients (46.7%) were able to have corticosteroid dose reductions of at least 50%, and performance status improved in six of 34 (20.6%) patients. Sixty percent of subjects experienced treatment-related, treatment-emergent adverse events (TR-TEAEs), including fatigue (34%), nausea (18%), decreased lymphocyte levels (14%). The most common serious adverse events were hydrocephalus (8%) and nausea (8%). Grade 3 TR-TEAEs occurred in 20%, most commonly fatigue (10%). One case each of seizure and pulmonary embolism were seen. There were no treatment-related deaths. The drug's prescribing information includes warnings and precautions for hypersensitivity, QTc interval prolongation, and embryo-fetal toxicity, according to the FDA statement. A phase 3 trial is underway to confirm the benefit of dordaviprone for recurrent H3 K27M-mutant diffuse glioma. M. Alexander Otto is a physician assistant with a master's degree in medical science and a journalism degree from Newhouse. He is an award-winning medical journalist who worked for several major news outlets before joining Medscape. Alex is also an MIT Knight Science Journalism fellow. Email: aotto@
Yahoo
29-07-2025
- Yahoo
Alumis (ALMS) Merges with ACELYRIN
Alumis Inc. (NASDAQ:ALMS) is one of the 11 Best New Penny Stocks to Buy Right Now. On May 21, Alumis Inc. (NASDAQ:ALMS) reported that it has completed its merger with ACELYRIN, Inc. As part of this transaction, each ACELYRIN shareholder will get 0.4814 shares of Alumis Inc. (NASDAQ:ALMS) common stock for every share of ACELYRIN they own. ACELYRIN has ceased trading. A clinical researcher in a lab examining a new biopharmaceutical product. Following this transaction, the company now has a much stronger balance sheet to support Alumis Inc. (NASDAQ:ALMS). This merger has created a leading clinical-stage immunology company with a diversified portfolio of product candidates. Additionally, this merger allows Alumis Inc. (NASDAQ:ALMS) to move forward with its plans and advance its pipeline through planned key data readouts. The company now has a cash runway that extends into 2027. Alumis Inc. (NASDAQ:ALMS) is a late-stage biopharma company focused on developing targeted therapies for a range of immune-mediated diseases. While we acknowledge the potential of ALMS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
